Pgi11 - High Levels of Reimbursed Cost and Use of Gastroenterological Drugs in France

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.854
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pmd160 - Pricing of Reimbursed Medical Devices in France: What Factors Impact Decision-Making?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Shortage of Drugs in France

Nature
Multidisciplinary
1942English

Php171 - Revisiting Reimbursed Drugs With Alternative Payment Model in Turkey: 2016-2018

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The High Cost of Cancer Drugs: What Can We Do?

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Pcn272 - Analysis of Pharmacy Claims for High Cost Drugs: Lenalidomide Utilisation and Expenditure in Ireland

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost of Inpatient Management of Hypoglycaemia in France

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Resource Use and Cost of Alzheimer’s Disease in France: 18-Month Results From the GERAS Observational Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

PHP114 Review of Cost Effectiveness Studies of High Budget Impact Drugs (2007-2012)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

France to Promote Sales of Generic Drugs

BMJ
2001English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy